Philips Wins Regulatory Nod for Clinical Surveillance Biosensor
Philips has won a nod from FDA and a CE mark for a next-generation wireless wearable biosensor to help monitor COVID-19 patients in hospital.
The Amsterdam, Netherlands-based company touts its next-generation device as being able to enhance clinical surveillance in its patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care in lower acuity care areas.
The Philips Biosensor BX100 is designed to address a new approach to vital signs measurements, supporting surveillance of higher acuity patients moving from intensive care units into lower acuity general care areas of a hospital.
The lightweight, disposable biosensor is a 5-day, single-use wearable patch that can be integrated with a scalable hub to monitor multiple patients across multiple rooms. Built to incorporate into existing clinical workflows for mobile viewing and notifications, the device requires no cleaning or charging.
“During this unprecedented time of COVID-19, the Philips Biosensor BX100 helps provide rapid deployment for clinical surveillance to help decrease risk of exposure of healthcare workers while acquiring frequent patient vitals, and easing the demand for personal protective equipment (PPE),” said Peter Ziese, General Manager Monitoring and Analytics at Philips. “The biosensor is an integral component in our Patient Deterioration Detection solution which helps aid in the identification of the subtle signs of deterioration in a patient’s condition at the point of care, hours before a potential adverse event would occur.”